PD-1 Inhibitors: Safety of Use and Management of Immune-Mediated Adverse Reactions in Patients With Head and Neck Cancer
| العنوان: | PD-1 Inhibitors: Safety of Use and Management of Immune-Mediated Adverse Reactions in Patients With Head and Neck Cancer |
|---|---|
| المؤلفون: | Rebecca L. Lewis, Kristen L Miller |
| المصدر: | Clinical Journal of Oncology Nursing. 23:627-638 |
| بيانات النشر: | Oncology Nursing Society (ONS), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Drug, medicine.medical_specialty, medicine.medical_treatment, media_common.quotation_subject, Programmed Cell Death 1 Receptor, Immune system, Programmed cell death 1, Health care, medicine, Humans, In patient, Neoplasm Metastasis, Intensive care medicine, General Environmental Science, media_common, biology, Squamous Cell Carcinoma of Head and Neck, business.industry, Head and neck cancer, Immunotherapy, medicine.disease, Discontinuation, Head and Neck Neoplasms, biology.protein, General Earth and Planetary Sciences, business |
| الوصف: | Background Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with programmed cell death protein 1 (PD-1) inhibitors has been associated with risk of developing immune-mediated adverse reactions (IMARs). Objectives This review provides nurses with an overview of the safety of PD-1 inhibitors approved by the U.S. Food and Drug Administration for recurrent or metastatic SCCHN following platinum chemotherapy, as well as recommendations for assisting with the diagnosis and management of IMARs. Methods PubMed® searches were conducted to identify relevant articles to support this review. Algorithms from drug manufacturers for IMAR management were also reviewed. Findings Before treatment with PD-1 inhibitors, nurses should map patients' baseline profiles, which play a key role in aiding the healthcare team in the timely diagnosis and treatment of IMARs. Nurses should educate patients and caregivers on identifying signs and symptoms of IMARs and their progression. Within the interprofessional healthcare team, nurses play an important role in ensuring efficient management of IMARs to minimize withholding or discontinuation of PD-1 immunotherapy. |
| تدمد: | 1538-067X 1092-1095 |
| DOI: | 10.1188/19.cjon.627-638 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc166bdf2e2b4f17e0b29abf8376a8c https://doi.org/10.1188/19.cjon.627-638 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0fc166bdf2e2b4f17e0b29abf8376a8c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1538067X 10921095 |
|---|---|
| DOI: | 10.1188/19.cjon.627-638 |